Test Bank for Clayton’s Basic Pharmacology for Nurses, 19th Edition by Willihnganz

Test Bank For Clayton’s Basic Pharmacology for Nurses 19th EditionBy
f f f f f f f f f f f



Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Complete
f f f f f f f f

,Chapter 01: Drug Definitions, Standards, and Information Sources Willihnganz:
f f f f f f f f f

Clayton’s Basic Pharmacology for Nurses, 19th Edition
f f f f f f




MULTIPLEfCHOICE

1. WhichfnamefidentifiesfafdrugflistedfbyfthefUSfFoodfandfDr
ugfAdministrationf(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS:f C
Thefofficialfnamefisfthef namefunderfwhichfafdrugfisflistedfbyft
hefFDA.fThefbrandfname,forftrademark,fisfthefnamefgivenftofaf
drugfbyfitsfmanufacturer.fThefnonproprietary,forfgeneric,fnam
efisfprovidedfbyfthefUnitedfStatesfAdoptedfNamesfCouncil.


DIF: CognitivefLevel:fKnowledge REF:f p.f9
OBJ:f1NAT:fNCLEXfClientfNeedsfCategory:fSafe,fEffectivefCarefE
nvironmentfTOP:f NursingfProcessfStep:fAssessment
CON:f
PatientfEducation

2. Whichfsourcefcontainsfinformationfspecificftofnutritionalfsupplements?
a. USPfDictionaryfoffUSANf &fInternationalfDrugfNames
b. NaturalfMedicinesfComprehensivefDatabase
c. UnitedfStatesfPharmacopoeia/NationalfFormularyf(USPfNF)
d. DrugfInteractionfFacts
ANS:f C
UnitedfStatesfPharmacopoeia/NationalfFormularyfcontainsfinformationfspecificftofnutritionalfsu
pplements.fUSPfDictionaryfoffUSANf&fInternationalfDrugfNamesfisfafcompilationfoffdrugfnames
,fpronunciationfguide,fandfpossibleffuturefFDAfapprovedfdrugs;fitfdoesfnotfincludefnutritionalfsu
pplements.fNaturalfMedicinesfComprehensivefDatabasefcontains
evidence-
basedfinformationfonfherbalfmedicinesfandfherbalfcombinationfproducts;fitfdoesfnotfincludefinfor
mationfspecificftofnutritionalfsupplements.fDrugfInteractionfFactsfcontainsfcomprehensivefinfor
mationfonfdrugfinteractionffacts;fitfdoesfnotfincludefnutritionalfsupplements.

DIF: CognitivefLevel:fKnowledge REF:f p.f4
OBJ:f3fNAT:f NCLEXfClientfNeedsfCategory:fPhysiologicalfIntegri
ty
TOP:f NursingfProcessfStep:fAssessment CON:f Nutritionf|fPatientfEducation

3. Whichfdrugfreferencefcontainsfdrugfmonographsfthatfdescribefallfdrugsfinfaftherapeuticfclass?
a. DrugfFactsfandfComparisons

,TestfBankfForfClayton’sfBasicfPharmacologyfforfNursesf19thfEdition 3

b. DrugfInteractionfFacts
c. HandbookfonfInjectablefDrugs
d. Martindale—ThefCompletefDrugfReference
ANS:f A
DrugfFactsfandfComparisonsfcontainsfdrugfmonographsfthatfdescribefallfdrugsfinfafthera
peuticfclass.fMonographsfarefformattedfasftablesftofallowfcomparisonfoffsimilarfproducts,f
brandfnames,fmanufacturers,fcostfindices,fandfavailablefdosagefformsfOnlinefversionfisf
available.

DIF: CognitivefLevel:fKnowledge REF:f p.f4fTablef1.2
OBJ:fff 3 NAT:f NCLEXfClientfNeedsfCategory:fPhysiologicalfIntegrity
TOP:f NursingfProcessfStep:fAssessment CON:f Safetyf|fPatientfEducationf|fClinicalfJudgment

4. Whichfdrugfreferencefcontainsfmonographsfaboutf virtuallyfeveryfsingle-
entityfdrugfavailablefinfthefUnitedfStatesfandfdescribesftherapeuticfusesfoffdrugs,fincludingfappr
ovedfandfunapprovedfuses?
a. Martindale:fThefCompletefDrugfReference
b. AHFSfDrugfInformation
c. Drugf Reference
d. DrugfFactsfandfComparisons
ANS:f B
AHFSfDrugfInformationfcontainsfmonographsfaboutfvirtuallyfeveryfsingle-
entityfdrugfavailablefinfthefUnitedfStatesfandfdescribesftherapeuticfusesfoffdrugs,fincludingfappro
vedfandfunapprovedfuses.

DIF: CognitivefLevel:fKnowledge REF:f p.f4fTablef1.2
OBJ:fff 3 NAT:f NCLEXfClientfNeedsfCategory:fPhysiologicalfIntegrity
TOP:f NursingfProcessfStep:fPlanning CON:f Safetyf|fPatientfEducationf|fClinicalfJudgment

5. Whichfonlinefdrugfreferencefmakesfavailableftofhealthcarefprovidersfandfthefpublicfafstandar
d,fcomprehensive,fup-to-dateflookfupfandfdownloadablefresourcefaboutfmedicines?
a. AmericanfDrugfIndex
b. AmericanfHospitalfFormulary
c. DailyMed
d. DrugfReference
ANS:f C
DailyMedfmakesfavailableftofhealthcarefprovidersfandfthefpublicfafstandard,fcomprehensive,fup-
to-
dateflookfupfandfdownloadablefresourcefaboutfmedicines.fThefAmericanfDrugfIndexfisfnotfappro
priatefforfpatientfuse.fThefAmericanfHospitalfFormularyfisfnotfappropriatefforfpatientfuse.fThefd
rugfreferencef isfnotfappropriatefforfpatientfuse.

DIF: CognitivefLevel:fKnowledge REF:f p.f3f|fp.f4
OBJ:f3fNAT:f NCLEXfClientfNeedsfCategory:fPhysiologicalfIntegri
ty
TOP:f NursingfProcessfStep:fImplementation
CON:f Safetyf|fPatientfEducationf|fClinicalfJudgment

6. WhichflegislationfauthorizesfthefFDAftofdeterminefthefsafetyfoffafdrugfbeforefitsfmarketing?
a. FederalfFood,fDrug,fandfCosmeticfActf(1938)
b. DurhamfHumphreyfAmendmentf(1952)

, TestfBankfForfClayton’sfBasicfPharmacologyfforfNursesf19thfEdition 4

c. ControlledfSubstancesfActf(1970)
d. KefauverfHarrisfDrugfAmendmentf(1962)
ANS:f A
ThefFederalfFood,fDrug,fandfCosmeticfActfoff1938fauthorizedfthefFDAftofdeterminefthefsafetyfo
ffallfdrugsfbeforefmarketing.fLaterfamendmentsfandfactsfhelpedftightenfFDAfcontrolfandfensurefd
rugfsafety.fThefDurhamfHumphreyfAmendmentfdefinesfthefkindsfoffdrugsfthatfcannotfbefusedfsa
felyfwithoutfmedicalfsupervisionfandfrestrictsftheirfsaleftofprescriptionfbyfaflicensedfpractitioner.f
ThefControlledfSubstancesfActfaddressesfonlyfcontrolledfsubstancesfandftheirfcategorization.fThe
fKefauverfHarris fDrugfAmendmentfensures fdrugfefficacyfandfgreaterfdrugfsafety.fDrugfmanufact

urersfarefrequiredftofproveftofthefFDAfthefeffectivenessfofftheirfproductsfbeforefmarketingfthem.

DIF: CognitivefLevel:fKnowledge REF:fp.f5fTablefl.3
OBJ:f 5
NAT:fNCLEXfClientfNeedsfCategory:fPhysiologicalfIntegrityfT
OP:f NursingfProcessfStep:fAssessment
CON:f Safetyf|fPatientfEducationf|fEvidencef|fHealthfCarefLaw

7. Whichfclassificationfdoesfmeperidinef(Demerol)ffallfunder?
a. I
b. II
c. III
d. IV
ANS:f B
Meperidinef(Demerol)fisfafSchedulefIIfdrug;fitfhasfafhighfpotentialfforfabusefandfmayfleadftofseve
refpsychologicalfandfphysicalfdependence.fSchedulefIfdrugsfhavefhighfpotentialfforfabusefandfnofr
ecognizedfmedicalfuse.fSchedulefIIIfdrugsfhavefsomefpotentialfforfabuse.fUsefmayfleadftoflowftof
moderatefphysicalfdependenceforfhighfpsychologicalfdependence.fSchedulefIVfdrugsfhaveflowfp
otentialfforfabuse.fUsefmayfleadftoflimitedfphysicalforfpsychologicalfdependence.

DIF: CognitivefLevel:fKnowledge REF:f p.f10
OBJ:f2fNAT:f NCLEXfClientfNeedsfCategory:fSafe,fEffectivefCarefE
nvironment
TOP:f NursingfProcessfStep:fAssessment CON:f PatientfEducationf|fAddictionf|fPain

8. WhichfactionfwouldfthefFDAftakeftofexpeditefdrugfdevelopmentf andfapprovalfforfanfoutbreakfoffs
mallpox?
a. Listfsmallpoxfasfafhealthforphanfdisease.
b. Omitfthefpreclinicalfresearchfphase.
c. Extendfthefclinicalfresearchfphase.
d. Fastftrackfthefinvestigationalfdrug.
ANS:f D
OncefthefInvestigationalfNewfDrugfApplicationfhasfbeenfapproved,fthefdrugfcanfreceivefhighestf
priorityfwithinfthefagency,fwhichfisfcalledffastftracking.fAfsmallpoxfoutbreakfwouldfbecomefafpri
orityfconcernfinfthefworld.fOrphanfdiseasesfarefnotfresearchedfinfafpriorityfmanner.fPreclinicalfre
searchfisfnotfomitted.fExtendingfanyfphasefoffthefresearchfwouldfmeanfaflongerftimeftofdevelopfafv
accine.fThefFDAfmustfensurefthatfallfphasesfoffthefpreclinicalfandfclinicalfresearchfphasefhavefbee
nfcompletedfinfafsafefmanner.

DIF: CognitivefLevel:fKnowledge REF:fffp.f7 OBJ:f 5